Water-drinking test in patients with primary open-angle glaucoma while treated with different topical medications

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 3, 2005, Pages 250-257

  Vetrugno, Michele ^a,c   Sisto, Dario ^a   Trabucco, Tiziana ^a   Balducci, Francesca ^b   Delle Noci, Nicola ^b   Sborgia, Carlo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; DORZOLAMIDE; LATANOPROST; TIMOLOL; TRAVOPROST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EYE FUNDUS; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MYDRIASIS; OCULOPLETHYSMOGRAPHY; OPEN ANGLE GLAUCOMA; OUTCOMES RESEARCH; PERIMETRY; SLIT LAMP; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD; WATER LOADING;

AGED; ANTIHYPERTENSIVE AGENTS; DRINKING; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; TIME FACTORS; WATER;

EID: 21644474822     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.250     Document Type: Article

References (50)

1. Kass, M.A., Heuer, D.K., and Higginbotham, E.J., Johnson, C.A., Keltner, J.L, Miller, J.P., Parrish, R.K., Wilson, M.R., and Gordon, M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medications delays or prevents thwe onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713, 2002.
2. Lichter, P.R., Musch, D.C., Gillespie, B.W., Guire, K.E., and Janz, N.K., Wren, P.A., Mills, R.P., and CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medication or surgery. Ophthalmology 108:1943-1953, 2001.
3. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS 7). The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130:429-440, 2000.
4. The Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with terapeutically reduced intraocular pressure. Am. J. Ophthalmol. 126:498-505, 1998.
5. Drance, S.M. The significance of the diurnal tension ariation in normal and glaucomatous eyes. Arch. Ophthalmol. 64:494-501, 1960.
6. Drance, S.M. Diurnal variation of intraocular pressure in treated glaucoma: significance in patients with chronic simple glaucoma. Arch. Opthalmol. 70:302-311, 1963.
7. Asrani, S., Zeimer, R., Wilensky, J., Gieser, D., Vitale, S., and Lindenmuth, K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma 9:134-142, 2000.
8. Konstas, A.G., Maltezos, A.C., Gandi, S., Hudgins, A.C., and Stewart, W.C. Comparison of 24-hour iontraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 128:15-20, 1999.
9. Larsson, L.I. Effect on intraocuar pressure during 24 hours after repeated administration of the fixed combation of latanoprost 0.0005% and timolol 0.5% in patients with ocular hypertension. J. Glaucoma 10: 109-114, 2001.
10. Mishima, H.K., Kiuchi, Y., Takamatsu, M., Racz, P., and Bito, L.Z. Circadian intraocular pressure management with latanoprost diurnal and nocturnal intraocular presure reduction and increased uveoscleral outflow. Surv. Ophthamol. 41:s139-s144, 1997.
11. Orzalesi, N., Rossetti, L., Ivernizzi, T., Bottoli A., and Autelitano, A. Effect of timolol, latanoprost and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invet. Ophthalmol. Vis. Sci. 41:2566-2573, 2000.
12. Orzalesi, N., Rossetti, L., Bottoli, A., et al. Comparison of latanoprost, brimonidine and a fixed combination of timolo-dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Invest. Ophthalmol. Vis. Sci. 42:5820, 2001.
13. th Edition. 1999 Mosby, p. 79.
14. American Academy of Ophthalmology Preferred Practice Patterns Committee Glaucoma Panel. Primary open-angle glaucoma. 2-4, 2000.
15. Rasmussen, K.E., and Jorgensen, H.A. Diagnostic value of the water-drinking test in early detection of simple glaucoma. Acta Ophthalmol. (Copenh) 54: 160-166, 1976.
16. Armaly, M.F. Lessons to be learned from the Collaborative Glaucoma Study. Surv. Ophthalmol. 25 139-144, 1980.
17. Roth, J.A. Inadequate diagnostic value of the water-drinking test. Br. J. Ophthalmol. 58:55-61, 1974.
18. Medeiros, F.A., Pinheiro, A., Moura, F.C., Lea, B.C., and Susanna, R. Intraocular pressure fluctuations in medically versus surgically treated gaucomatous patients. J. Ocul. Pharmacol. Ther. 18:489-498, 2002.
19. Brucculeri, M., Hammel, T., Harris, A., Malinovsky, V., and Martin, B. Regulation of intraocular pressure after water drinking. J. Glaucoma 8:111-116, 1999.
20. Diestelhorst, M., and Krieglstein, G.K. The effect of water-drinking test on aqueous humor dynamiucs in healthy volunteers. Graefe's Arch. Clin. Exp. Ophthamol. 232:145-147, 1994.
21. Toris, C.B., Gleason, M.L., Camras, C.B., and Yablonski, M.E. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol. 113: 1514-1517, 1995.
22. Toris, C.B., Camras, C.B., and Yablonski, M.E. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am. J. Ophthalmol. 128:8-14, 1999.
23. Brubaker, R.F., Schoff, E.O., Nau, C.B., Carpenter, S.P., Chen, K., and Vandenburgh, A.M. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am. J. Ophthalmol. 131:19-24, 2001.
24. Christiansen, G.A., Nau, C.B., McLaren, J.W., and Johnson, D.H. Mechanism of ocular hypotensive action of Bimatorpost (Lunigan) in patients with ocular hypertension or glaucoma. Ophthalmology 111:1658-1662, 2004.
25. Sherwood, M., and Brandt, J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. 45(Suppl. 4):S361-S368, 2001.
26. Brandt, J.D., VanDenburgh, A.M., Chen, K., and Whitcup, S.M. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 108:1023-1031, discussion 1032, 2001.
27. Higginbotham, E.J., Schuman, J.S., Goldberg, L, Gross, R.L., VanDenburgh, A.M., Chen, K., and Whitcup, S.M. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch. Ophthalmol 120:1286-1293, 2002.
28. Whit cup, S.M., Cantor, L.B., VanDenburgh, A.M., and Chen, K. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br. J. Ophthalmol. 87:57-62, 2003.
29. Netland, P.A., Landry, T., Sullivan, E.K., Andrew, R., Silver, L., Weiner, A., Mallick, S., Dickerson, J., Bergamini, M.V., Robertson, S.M., and Davis, AA. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophtlmlmol. 132:472-484, 2001.
30. Goldberg, I., Cunha-Vaz, J., Jakobsen, J.E., Nordmann, J.P., Trost, E., and Sullivan, EK. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma 10:414-422, 2001.
31. Fellman, R.L., Sullivan, E.K., Ratliff, M., Silver, L.H., Whitson, J.T., Turner, F.D., Weiner, A.L., and Davis, AA. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 109:998-1008, 2002.
32. Aim, A., and Srjernschantz, J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743-1752, 1995.
33. Camras, C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138-147, 1996.
34. Mishima, H.K., Masuda, K., Kitazawa, Y., Azuma, I., and Araie, M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch. Ophthalmol. 114:929-932, 1996.
35. Camras, C.B., Wax, M.B., Ritch, R., Weinreb, R., Robin, A.L., Higginbotham, E.J., Lustgarten, J., Stewart, W.C., Sherwood, M., Krupin, T., Wilensky, J., Cioffi, G.A., Katz, L.J., Schumer, R.A., Kaufman, P.L., Minckler, D., Zimmerman, T., and Srjernschantz, J. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. Am. J. Ophthalmol. 126:390-399, 1998.
36. Konstas, A.G., Maltezos, A.C., Gandi, S., Hudgins, A.C., and Stewart, W.C. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 128:15-20, 1999.
37. Aim, A., and Widengård, I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol. Scand. 78:71-76, 2000.
38. Hedman, K., and Aim, A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur. J. Ophthalmol. 10:95-104, 2000.
39. Schuman, J.S. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv. Ophthalmol. 41 (Suppl. 1):S27-S37; 1996.
40. Schuman, J.S., Horwitz, B., Choplin, N.T., David, R., Albracht, D., and Chen, K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch. Ophthalmol. 115:847-852, 1997.
41. LeBlanc, R.P. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 105:1960-1967, 1998.
42. Katz, LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am. J. Ophthalmol. 127:20-26, 1999.
43. Melamed, S., and David, R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin. Ther. 22:103-111, 2000.
44. Wilkerson, M., Cyrlin, M., Lippa, E.A., Esposito, D., Deasy, D., Panebianco, D., Fazio, R., Yablonski, M., and Shields, MB. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch. Ophthalmol. 111:1343-1350, 1993.
45. Strahlman, E., Tipping, R., and Vogel, R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol: International Dorzolamide Study Group. Arch. Ophthalmol. 113: 1009-1016, 1995.
46. Strahlman, E., Tipping, R., and Vogel, R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group. Am. J. Ophthalmol. 122:183-194, 1996.
47. Maus, T.L., Larsson, L.I., McLaren, J.W., and Brubaker, RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch. Ophthalmol. 115:45-49, 1997.
48. Heijl, A., Strahlman, E., Sverrisson, T., Brinchman-Hansen, O., Puustjärvi, T., and Tipping, R. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology 104:137-142, 1997.
49. Adamsons, I.A., Polis, A., Ostrov, C.S., and Boyle, J.E. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. J. Glaucoma 7:395-401, 1998.
50. Warter, G., and Jeannenot, N. Increased intraocular pressure provoked by a water test. Ophthalmologica 202:75-80, 1991.